SCHEMBL2880697

SCHEMBL2880697

CN(Cc1ccccc1Cl)C(=O)CCl

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
RAB9A P51151 5/20 0.56
HTT P42858 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
PYCR1 P32322 1/20 0.47
KDM4E B2RXH2 1/20 0.46
TAAR1 Q96RJ0 1/20 0.44
NPC1 O15118 3/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TACR1 P25103 1/20 0.43
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419274 0.82 MEN1 (0.54) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL8672261 0.80 ALDH1A1 (0.61) ALDH1A1RAB9AHTTSMN1; SMN2KMT2A
SCHEMBL19027274 0.78 MEN1 (0.50) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL17887845 0.77 MEN1 (0.52) ALDH1A1RAB9AHTTSMN1; SMN2KMT2A
SCHEMBL991685 0.77 RAB9A (0.72) ALDH1A1RAB9AHTTSMN1; SMN2KMT2A
SCHEMBL17882313 0.76 RIPK1 (0.71) BCHEACHE
SCHEMBL8668061 0.76 NPC1 (0.53) ALDH1A1RAB9AHTTSMN1; SMN2KMT2A
SCHEMBL31186765 0.74 RAB9A (0.54) ALDH1A1RAB9AHTTSMN1; SMN2KMT2A
SCHEMBL11978824 0.74 PYCR1 (0.56) ALDH1A1RAB9AKMT2AMEN1BCHE
SCHEMBL6414043 0.73 MEN1 (0.46) ALDH1A1RAB9AKMT2AMEN1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121638-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME (US) 2016-05-25 EP disclosed
EP-2222661-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME (US) 2016-04-20 EP disclosed
US-8404856-B2 Non-nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2013-03-26 US disclosed
US-20100286192-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTHONY NEVILLE J 2010-11-11 US disclosed
US-20100256181-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME LLC 2010-10-07 US disclosed
US-7781454-B2 Non-nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-08-24 US disclosed
EP-2121638-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20080275097-A1 Non-nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME LLC 2008-11-06 US disclosed
WO-2008076225-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275097-A1 Non-nucleoside reverse transcriptase inhibitors RNGTT, RRM2B, RRM2 ALDH1A1 2863/4885RAB9A 1087/4885HTT 4329/4885
US-20100286192-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RNGTT, RRM2B, RRM2 ALDH1A1 2863/4885RAB9A 1087/4885HTT 4329/4885
US-20100256181-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS POLB, POLR2A, RRM2B ALDH1A1 2088/4885RAB9A 662/4885HTT 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.